Bristol plunges, Merck jumps, on contrasting lung cancer data

(Reuters) - Bristol-Myers Squibb Co shares plunged almost 10 percent after researchers said lung cancer patients fared worse on its Opdivo immunotherapy than those on chemotherapy, while shares of Merck & Co jumped 2 percent on strong benefits shown by its rival drug in a similar late-stage study.